1
|
Albuquerque KMCD, Joventino CB, Moreira LC, Rocha HAL, Gurgel LA, Oliveira DDS, Rodrigues CEM. Clinical outcome and prognosis of patients with acute myeloid leukemia submitted to chemotherapy with 5 years of follow-up. Hematol Transfus Cell Ther 2024; 46:8-13. [PMID: 36564332 PMCID: PMC10935468 DOI: 10.1016/j.htct.2022.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 09/12/2022] [Accepted: 11/13/2022] [Indexed: 12/12/2022] Open
Abstract
OBJECTIVE The purpose of this study was to evaluate the clinical-epidemiological profile, associated risk factors and clinical outcomes of patients with acute myeloid leukemia (AML), identifying the main causes of morbidity and mortality and overall survival rate of patients at five years of follow-up. METHOD This was a retrospective cohort study evaluating the prognosis and clinical outcomes of 222 patients diagnosed with AML at three large hematology centers in Ceará (northeastern Brazil) over a period of five years. RESULTS The mean age at diagnosis was 44.1 ± 16 years, with a female prevalence of 1.3:1. No additional relevant risk factors associated with the development of AML were found, except for the well-established cytogenetic assessment. The overall 5-year survival rate was 39.4% (95%CI: 35.47 - 42.17). The main causes of death were disease progression (37.72%; n = 84) and sepsis (31.58%; n = 70). CONCLUSION The clinical outcomes in our sample of AML patients were similar to those of other reported groups. Disease progression and infection were the main causes of death. Access to diagnostic flow cytometry and karyotyping was greater in our sample than in the national average. As expected, overall survival differed significantly according to the risk, as determined by cytogenetic testing.
Collapse
Affiliation(s)
| | | | | | | | - Lívia Andrade Gurgel
- Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
| | - Deivide de Sousa Oliveira
- Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
| | - Carlos Ewerton Maia Rodrigues
- Universidade de Fortaleza (Unifor), Fortaleza, CE, Brazil; Fortaleza General Hospital (HGF), Fortaleza, CE, Brazil; Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil
| |
Collapse
|
2
|
Datoguia TS, Velloso EDRP, Helman R, Musacchio JG, Salvino MA, Soares RA, Higashi M, Fadel AV, E Silva RSA, Hamerschlak N, Santos FPDS, Campregher PV. Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a cross-sectional study. Med Oncol 2018; 35:141. [PMID: 30187210 DOI: 10.1007/s12032-018-1179-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 06/19/2018] [Indexed: 10/28/2022]
Abstract
Prognostic stratification in acute myeloid leukemia (AML) relies, mostly, on cytogenetics and molecular features of leukemic blasts. The LeukemiaNet prognostic scoring system has been proposed as a standardized way of evaluating prognosis in AML. We have analysed outcomes in 65 AML cases (median age of 54 years, range 18-82) treated at five hematology centers in Brazil stritified according to the European Leukemia Net (ELN) recommendations for cytogenetic and molecular analysis. We classified patients as favorable (N = 13), intermediate-1 (N = 25), intermediate-2 (N = 15), or adverse risk (N = 9). Bone marrow transplantation (BMT) was performed in 13 patients (21%). Median follow-up was 12 months. The median overall survival (OS) for all patients was 12.4 months. Median OS was 19.8, 12.4, 10.1, and 10.4 months (p = 0.24) for patients in the favorable, intermediate-1, intermediate-2, and adverse groups, respectively. Among patients receiving BMT, median OS was 26.8 months. The ELN is a valuable tool for prognostic stratification of AML patients treated in Brazil. Nevertheless, its usefulness is limited when compared to data from developed countries.
Collapse
Affiliation(s)
- Tarcila Santos Datoguia
- Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
| | | | - Ricardo Helman
- Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
| | | | - Marco Aurélio Salvino
- Complexo Hospitalar Universitário Professor Edgard Santos (HUPES), Universidade Federal da Bahia (UFBA), Salvador, Brazil
| | | | | | | | | | - Nelson Hamerschlak
- Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
| | | | - Paulo Vidal Campregher
- Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil. .,Centro de Pesquisa Clínica, Instituto Israelita de Ensino e Pesquisa Albert Einstein, Av. Albert Einstein, 627/520, São Paulo, CEP 05256-900, Brazil.
| |
Collapse
|